Efficacy of MiniMed ™ 780G ® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMed ™ 770G ®: A 3‐month prospective single‐center observational study

Aims/Introduction The MiniMed™ 780G® is effective for improving glycemic control; however, few studies have specifically examined the impact of upgrading from MiniMed™ 770G® to MiniMed™ 780G® in adults. We determined the effects of upgrading from MiniMed™ 770G® to MiniMed™ 780G® (780G) on glucose management, psychological distress, daily life quality, and sleep in type 1 diabetes mellitus (T1DM). Materials and Methods In this single‐center prospective study, we observed 21 adults who transitioned from the MiniMed™ 770G® to the 780G for 3 months. Glycemic outcomes, insulin delivery parameters, frequency of alarms, and sensor calibrations were assessed. Patient‐reported outcomes were evaluated using the Problem Areas in Diabetes (PAID), the Diabetes Treatment Satisfaction Questionnaire status version, the Diabetes Therapy‐Related Quality of Life, and the Pittsburgh Sleep Quality Index. Results Glycated hemoglobin (HbA1c) decreased (7.5 ± 1.3%–7.0 ± 0.8%, mean difference: −0.5%, 95% Confidence Interval (CI): −0.9 to −0.1; P = 0.018). Time in tight range (TITR) showed trends toward improvement (44.9 ± 15.5%–48.9 ± 15.5%, mean difference: 4.0%, 95% CI: −0.7 to 8.6; P = 0.090). Alarm frequency declined (11.9 ± 8.7–7.1 ± 5.5 times/day, mean difference: −4.8, 95% CI: −7.0 to −2.6; P = 0.0002), and calibration frequency decreased (3.6 ± 2.2–0.8 ± 0.6 times/day, mean difference: −2.8, 95% CI: −3.7 to −1.9; P < 0.0001). The PAID score improved, decreasing from 38.7 ± 19.9 to 31.7 ± 19.3 (mean difference: −7.0, 95% CI: −14.7 to 0.7; P = 0.074). Conclusions Favorable changes in HbA1c, TITR, and PAID scores suggest potential glycemic and psychological benefits.